baltimore conference logo
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Clinical Cases in Relapsed and Refractory DLBCL

Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.

EP. 1: Case 1: Relapsed DLBCL, Transplant Eligible

October 28th 2020

EP. 2: Case 1: Waiting for FISH Results in DLBCL

October 28th 2020

EP. 3: Case 1: Identifying Patients for CNS Prophylaxis in DLBCL

October 28th 2020

EP. 4: Case 1: Outcomes in Chemotherapy-Treated Patients With DLBCL

October 28th 2020

EP. 5: Case 1: Therapy for Relapsed DLBCL in Transplant-Eligible Patients

October 28th 2020

EP. 6: Case 1: Trials in CAR T-Cell for Patients With Relapsed/Refractory DLBCL

October 28th 2020

EP. 7: Case 1: Therapeutic Options After CAR T-Cell in Relapsed/Refractory DLBCL

October 28th 2020

EP. 8: Case 2: R-CHOP Refractory DLBCL, Transplant Ineligible

October 28th 2020

EP. 9: Case 2: Therapeutic Options in Patients With Transplant-Ineligible, Treatment-Refractory DLBCL

October 28th 2020

EP. 10: Case 2: Considerations for Choosing a Second-Line Therapy for DLBCL

October 28th 2020